The Evolving Landscape of Differentiated Thyroid Cancer Treatment

Medical oncologists and endocrinologists discuss approaches to the management of patients with differentiated thyroid cancer.

EP. 1: Classifying Thyroid Cancer

December 17th 2021

Giuseppe Barbesino, MD, highlights the various types of thyroid cancers and comments on how their differences impact management.

EP. 2: Thyroid Cancer Risk Factors

December 17th 2021

Naifa L. Busaidy, MD, FACP, FACE, comments on risk factors associated with the subtypes of thyroid cancers.

EP. 3: Diagnostic Criteria Used in Differentiated Thyroid Cancer

December 17th 2021

Signs and symptoms of differentiated thyroid cancer and recommendations for establishing an accurate diagnosis.

EP. 4: RAI-Refractory Differentiated Thyroid Cancer

December 17th 2021

The typical diagnostic work-up for patients with advanced differentiated thyroid cancer, the rationale for treating patients with radioactive iodine (RAI), and a definition of RAI-refractory disease.

EP. 5: Molecular Testing Approaches for RAI-Refractory DTC

January 7th 2022

Marcia Brose, MD, PhD, FASCO, and Maria E. Cabanillas, MD, compare the use of molecular testing for radioactive iodine-refractory differentiated thyroid cancer at their institutions and highlight predictive and prognostic biomarkers.

EP. 6: Establishing Treatment Goals and Monitoring Patients With DTC

January 7th 2022

Criteria used by endocrinologists/oncologists to establish goals of therapy for patients with differentiated thyroid cancer, and recommendations for active surveillance.

EP. 7: Thyrotropin Suppression for Differentiated Thyroid Cancer

January 14th 2022

The pros and cons of thyrotropin suppression as treatment for patients with differentiated thyroid cancer.

EP. 8: Approaches to Monitoring Patients With Differentiated Thyroid Cancer

January 14th 2022

Marcia Brose, MD, PhD, FASCO, explains how she counsels and monitors patients with differentiated thyroid cancer and indicators to initiate therapy.

EP. 9: When to Initiate Therapy for Differentiated Thyroid Cancer

January 21st 2022

Maria E. Cabanillas, MD, describes what triggers her to initiate therapy for differentiated thyroid cancer and variables that impact treatment choice.

EP. 10: Targeted Treatments for Differentiated Thyroid Cancer

January 21st 2022

An overview of the types of targeted drug classes available to treat differentiated thyroid cancer at various clinical stages.

EP. 11: Systemic Therapy Algorithms in DTC

January 28th 2022

Considerations regarding approaches to sequencing therapies for differentiated thyroid cancer.

EP. 12: RET and NTRK Inhibitors for Differentiated Thyroid Cancer

January 28th 2022

The rationale for targeting actionable mutations in differentiated thyroid cancer with RET and NTRK inhibitors.

EP. 13: BRAF Inhibitors and Immunotherapy for Differentiated Thyroid Cancer

February 3rd 2022

The role of BRAF inhibitors and checkpoint inhibitors in differentiated thyroid cancer, and potential considerations for using BRAF inhibition as redifferentiation therapy.

EP. 14: Second-Line Treatment Approaches for DTC

February 3rd 2022

Naifa L. Busaidy, MD, FACP, FACE, recognizes the importance of reassessing patients prior to considering a second-line therapy for differentiated thyroid cancer.

EP. 15: Novel Treatment Advances in Differentiated Thyroid Cancer

February 3rd 2022

An overview of therapies in the pipeline for differentiated thyroid cancer and their potential effect on clinical decision-making.